Dos noticias que a los endocrinos nos tienen rascando la cabeza :
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Nov 2022 – Aug 2025Where it's discussed
-
X / Twitter190 posts
-
News75 articles
-
Blogs6 articles
-
Facebook4 posts
-
Bluesky3 posts
-
YouTube2 videos
-
Reddit2 posts
AI synopsis
What people are saying
Contributors generally emphasize the findings of the study, referencing phrases like '58% increased risk of all thyroid cancers' and '78% increased risk of medullary thyroid cancer' to illustrate their concerns. The tone of the discussions is a mix of alarm and curiosity, as seen in comments urging readers to consult medical professionals before starting GLP-1 RA medications. The choice of words such as 'must consider' and 'increased risk' conveys a sense of urgency and importance regarding the topic.
The majority of discussions demonstrate strong support for the findings and the concerns raised in the publication about thyroid cancer risks linked to GLP-1 receptor agonists.
There is evident enthusiasm and curiosity among contributors regarding the implications of the research, as many express the need for further details and clarification.
While many discussions touch on the publication's details, few delve deeply into the broader implications or personal experiences, indicating moderate engagement.
Many participants perceive the research as significantly impactful, highlighting its relevance to public health and medical practice.
Abstract in brief
- This study investigates whether GLP1 receptor agonists (RA) increase the risk of thyroid cancer in patients with type 2 diabetes.
- The analysis used data from the French national health care system, comparing 2562 thyroid cancer patients to 45184 controls matched by age, sex, and diabetes duration.
- Results indicated a higher risk of thyroid cancer overall, and specifically medullary thyroid cancer, linked to 13 years of GLP1 RA treatment.
Top posts
Most liked on X and BlueskyGLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhmal https://t.co/73VNByrOLY https://t.co/Ngb6ObhcS5
Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased risk of thyroid cancer. #Pharmacoepi @DrugsSafe Read Here➡️https://t.co/s0PAaHPbq5 https://t.co/JOOd98Yo8i
New study is pretty clear: “In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.” $NVO $LLY https://t.co/CnDZcEhtGD
NEW: drug safety update on GLP-1 and dual GIP/GLP-1 receptor agonists and the risk of pulmonary aspiration during anaesthesia or deep sedation. The MHRA emphasises individualised risk assessment and asking patients directly about these medications: ow.ly/Rl1x50UQ5xu
All mentions
Do GLP-1 Receptor Agonists Increase Thyroid Cancer Risk?
GLP-1 Receptor Agonists and Thyroid Cancer Risk Assessment
This video discusses the potential risks associated with GLP-1 receptor agonists, particularly the connection to thyroid cancer. It examines findings from studies related to the increased risk of thyroid cancer…
https://t.co/Yy2C0WYIRT
C-celtumoren komen voor in de schildklier bij blootstelling aan GLP-1-receptoragonisten. Hogere percentages schildklierkanker bij mensen die semaglutide gebruikten, vooral na 1 tot 3 jaar gebruik. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/1W5n94xoWD https://t.co/6agdzTj2Nc
RT @Fraslin: Une vaste étude française a observé une augmentation du risque de cancer de la thyroïde, notamment sous sa forme médullaire, c…
Une vaste étude française a observé une augmentation du risque de cancer de la thyroïde, notamment sous sa forme médullaire, chez les utilisateurs de GLP-1 pendant un à trois ans. Les chercheurs ont également constaté que ce risque restait légèrement https://t.co/krboiZe4el
@jenstaffeldt @Mangan150 oxidative stress and monocyte-driven inflammation. Exercise directly lowers cytokines like IL-6 and TNF-α via anti-inflammatory pathways. Did your doctor mention the increased risk of thyroid cancer using GLP1’s ? https://t.co/FGHHBxWRxR
@Stumpeed @upRootNutrition There is always risk. Risk is not a bad thing, it is a part of life. Risk is a thing to monitor, evaluate, and adjust as needed. Case in point: https://t.co/U4R7Eb4ICf
GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study - Surgery for Obesity and Related Diseases www.soard.org/article/S155...
Glp1 agonists associated with increased risk of all types of thyroid cancer https://t.co/dvfDCthNqW @MakisMD @RobertKennedyJr
@john_ford77 @DalgetySusan https://t.co/WJDOBijykX
NEW: drug safety update on GLP-1 and dual GIP/GLP-1 receptor agonists and the risk of pulmonary aspiration during anaesthesia or deep sedation. The MHRA emphasises individualised risk assessment and asking patients directly about these medications: ow.ly/Rl1x50UQ5xu
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Diabetes Care | American Diabetes Association https://t.co/cjG2k5XN1F
@CollinRugg Risk of all thyroid cancers with use of Glp-1 medications. https://t.co/vGu6ev2giN
@DrNadolsky They aren’t as amazing as you claim them to be: A published study in Diabetes Care revealed a 58% increased risk of all thyroid cancers and a 78% increased risk of medullary thyroid cancer in users of GLP-1 receptor agonists over 1-3 years. https://t.co/gYg56GaPcM 5.1% (1 in
RT @hanan052020: @inorii_yuzuriha https://t.co/Uq6UnKjT1K https://t.co/3swKNuKA7Y
@inorii_yuzuriha https://t.co/Uq6UnKjT1K https://t.co/3swKNuKA7Y
Ozempic is a GLP-1 like Receptor Agonists and scientist have found a link between drugs with GLP-1 and Thyroid Cancer after a 1-3 year treatment. Biden is proposing Medicare to cover Ozempic for millions of Americans who are not diabetic, but simply overweight. pubmed.ncbi.nlm.nih.gov/36356111/
@CoffeeBlackMD @AviBittMD From the article, but it's made up?
@dutchyankee2 @Tellit007 @Constantin22409 @newstart_2024 https://t.co/NFji0jukQw
@Limeoff @MaraStrega https://t.co/AV7k0GoFE7 Но конечно же, есть тонкости — после 1-3 лет употребления (никто кроме диабетиков не колет оземпик год), и риск ничтожный, его увеличение на 60% точно так же ничтожно.
RT @AmThyroidAssn: Read Dr. Theodora Pappa's 2023 Rosalind Franklin Society (RFS) Award in Science article for her outstanding work in @cli…
RT @AmThyroidAssn: Read Dr. Theodora Pappa's 2023 Rosalind Franklin Society (RFS) Award in Science article for her outstanding work in @cli…
Read Dr. Theodora Pappa's 2023 Rosalind Franklin Society (RFS) Award in Science article for her outstanding work in @clinicalthyroid: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. https://t.co/Axs0MpFKch #thyroidcancer #ThyroidHealth @GDATF @ThyCaInc @TheEndoSociety https://t.co/XMHZidXQXu
@bioinvestor24 Remarkably safe to be sure, but definitely not “nothing” on the safety front. Suicidal ideation and thyroid carcinoma are two potential safety events to monitor for GLP-1! https://t.co/1FDP69LttJ https://t.co/47M2S9xf3n
@ymargham Relating this to endocrine cancers, GLP-1 receptor agonists have been associated with an increased risk of medullary thyroid cancers. Bezin J et. al GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023 Feb 1;46(2):384-390. doi: 10.2337/dc22-1148.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Clinical Thyroidology® https://t.co/oEc7WkQPo0
@animacava @Mael1Radec A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1–3 years was associated with increased risk of all thyroid cancer. https://t.co/lUTUzC0wFk Скорректированный коэффициент риска
@ArbleMatan מקור על הערכת הסיכון בבני אדם: https://t.co/tWbcwRiVfI
@DeryaTR_ İskandinav çalışması dışında veriler o doğrultuda değil değil Sayın Hocam. https://t.co/QHMt135F6r
@EndoDialogues https://t.co/qPfb2uAenA just a thought
@dutchyankee2 @BettyDavisEyess @DrNadolsky Humans. 2,562 case subjects with thyroid cancers matched with 45,184 control subjects. "In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment." https://t.co/avsE3u6eY1
@PhunkNemo @RyanPatrickHef1 @BioLayne Humans... - 2,562 case subjects with thyroid cancers included, matched with 45,184 control subjects. "we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment." https://t.co/bMP2HfwaaY
@jaeholee_dev @vhender_ "glp-1 receptor agonists and the risk of thyroid cancer" 프랑스인 2500명으로 실험한 논문에서는 연관 있다고 나오는걸보니 아직 제대로 정립된건 아닌거같습니다.
https://t.co/KmA9G2Rruq Including this paper, @EMA_News found no causal association
RT @peter_mantas: New study is pretty clear: “In the current study we found increased risk of all thyroid cancer and medullary thyroid canc…
RT @peter_mantas: New study is pretty clear: “In the current study we found increased risk of all thyroid cancer and medullary thyroid canc…
New study is pretty clear: “In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.” $NVO $LLY https://t.co/CnDZcEhtGD
@bmj_latest Don't forget the increase in thyroid cancer! "In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment." https://t.co/XQpW0Og4YF
@elonmusk @Walmart An important side effect to consider: https://t.co/giMetupDL7
Great article: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. https://t.co/nz8v9CSYu5 #ReadByQxMD
اما هذي توتر صراحة بس مادرست Semaglutide https://t.co/dSa7quahEd
@skathire So that's way less beneficial than eating more to the direction of Mediterranean diet: https://t.co/g1ocMAYH9d without the 58%-78% increased risk of thyroid cancers: https://t.co/lUw2vdmTL8 https://t.co/BSgT4HVHbs
@JustJewels93 Here's some more info. I'd usually. EVER share anything ADA bc they're a horrible org IMO BUT I did find this summary: https://t.co/AZ2sdL3O4G
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023 Feb 1;46(2):384-390. doi: 10.2337/dc22-1148. PMID: 36356111.
RT @lpietrzak20: Stosowanie analogów GLP-1 (dulaglutydu, liraglutydu, semaglutydu) może zwiększać ryzyko występowania wszystkich nowotworów…
Stosowanie analogów GLP-1 (dulaglutydu, liraglutydu, semaglutydu) może zwiększać ryzyko występowania wszystkich nowotworów tarczycy. https://t.co/b370gefkqS
@cycl0n3_sw0rd @GOONMEAT_ @DannyJBauer Semaglutide is a GLP-1 receptor agonist and that drug group is linked with increased thyroid cancer. https://t.co/pPZUSar0Af It’s even part of the medication counseling/informed consent any decent medical practitioner needs to discuss with the patient before starting a GLP-1RA.
@tracyktownsend "the effects on humans are unknown" https://t.co/YWtRSkbz6R
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer: https://t.co/n0EtW0Ypja https://t.co/9FJSjU47nc https://t.co/HWfxrOGMz9
More data is needed
@ZubyMusic @elonmusk I saw this retro French study abstract in Feb and I got freaked: https://t.co/y5jsKbvBsh
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/PD8YqLXMun
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/RRrKZFUo7C
Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:3… https://t.co/jmTTFRooim
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/ePB13b6wsM
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/F3pp7A9XCb https://t.co/r1QjPLk6u9
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/5GNGhIukuP
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390 https://t.co/Pr4YmjyjVH https://t.co/UsEwerSAVT
Journal Club SID GLP-1 e tiroide: nemici o amici? - A cura di Maurizio Di Marco e Federica Vinciguerra https://t.co/AS8x3p2zzt
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @IlindelatorreMD: Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
Agonistas del receptor GLP-1 y el riesgo de cáncer de tiroides. https://t.co/O5mVQ9UDum https://t.co/fDBoXPkKTv
RT @agingdoc1: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/TrTfHYlWu6 https://t.co/OyJbjjhy7g
RT @agingdoc1: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/TrTfHYlWu6 https://t.co/OyJbjjhy7g
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/TrTfHYlWu6 https://t.co/OyJbjjhy7g
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/yJ2AHiLnyq
Posting this because I hear so many people "wondering" if there are increased risks of thyroid cancer in humans with GLP1 agonists like Ozempic. Yes: https://t.co/G7ovPMlqVL #reversedisease #metabolichealth #Olympic #glp1
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/YAa5TDlekJ
RT @koki_fitness: 劇的なダイエット効果が期待できる、ダイエット薬で甲状腺がんのリスクが上がるかもしれないというデータがアメリカ糖尿病学会の雑誌に掲載 ダイエット薬は劇的な効果が高い一方で、服薬を止めたらリバウンドするなどのデメリットもあります https:…
劇的なダイエット効果が期待できる、ダイエット薬で甲状腺がんのリスクが上がるかもしれないというデータがアメリカ糖尿病学会の雑誌に掲載 ダイエット薬は劇的な効果が高い一方で、服薬を止めたらリバウンドするなどのデメリットもあります https://t.co/w9TuxLN4Lr
RT @LiebertPub: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer A new study in @clinicalthyroid adds important insight from real-wo…
RT @LiebertPub: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer A new study in @clinicalthyroid adds important insight from real-wo…
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Clinical Thyroidology https://t.co/vCBdQY8U5P
RT @LiebertPub: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer A new study in @clinicalthyroid adds important insight from real-wo…
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer A new study in @clinicalthyroid adds important insight from real-world practice on the potential link of #GLP1 receptor agonists with #thyroidcancer: https://t.co/0Tz8rfRord https://t.co/4QVJSCFOuQ
@scottisaacsmd @DanielJDrucker Thoughts? https://t.co/ehKIjrPeIP
@SamirTabar @Rob_NBF https://t.co/xU5if3gK6H https://t.co/pCYtdIyC9B
@nachX @Steelermilltown @nicknorwitz True. And humans: https://t.co/E8tbsKFKrV
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Use of #GLP1 RA for 1–3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio a-HR=1.58; 1.27–1.95) and medullary thyroid cancer (adjusted HR=1.78; 1.04–3.05). https://t.co/Qlmc2G98cX https://t.co/mx9CHXZAwd
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @endocrinorosero: Dos noticias que a los endocrinos nos tienen rascando la cabeza :
Dos noticias que a los endocrinos nos tienen rascando la cabeza :
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
Nada es inocuo y nada supera el ejercicio
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Diabetes Care | American Diabetes Association https://t.co/5GIxZ9LWa4
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/vIrPfPsOe7
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
RT @docmaltese: GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhm…
GLP-1 receptor agonists and risk of thyroid cancer -via @DiabetesCareADA @XarisKoufakis @DrMohgah @cristinatejerap @tejhmal https://t.co/73VNByrOLY https://t.co/Ngb6ObhcS5
Ojo pues hay información clara del aumento de riesgo de cáncer en humanos! Sugiero revisar este paper https://t.co/98bDfoFmvh Y SIEMPRE consultar con su médico antes de tomar decisiones sobre su salud, sobre todo si implica administrar medicamentos!! https://t.co/PZKB1hoWo0
@DanielJDrucker Hey Daniel, curious to get your thoughts on the recently published French retrospective study on thyroid cancer in GLP1RA therapy (HR: 1.58) https://t.co/d89MiIRqou
I'm going to start including TFTs and thyroid history as part of my baseline and routine monitoring. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/5vHdteP0ax
@EricTopol Thank you for putting this together. I do wonder about the theoretical risk of thyroid cancer seen in preclinical studies. This recent population based study suggests more defined monitoring might be helpful. https://t.co/A7MTGuGfWp
RT @AdrianSotoMota: @DrGiovanniD Y esa seguridad a largo plazo sigue en estudio. https://t.co/gHNW0m1bPw
@DrGiovanniD Y esa seguridad a largo plazo sigue en estudio. https://t.co/gHNW0m1bPw
@IdoWolf1 "In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment" https://t.co/mqD8H3Bz5E
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/0ztFYxzQaB OJO
Ref: https://t.co/qNuWUXcuff
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/TucaMliVJQ
https://t.co/r9mEpjcFdv
@AviBittMD A pill for an ill With a side risk of cancer. What could possibly go wrong. I’m sure the high profit margins have nothing to do with any of this https://t.co/LvLTQOnmzP.
RT @JorRuizSanchez: ¿Quién ha leído el impactante artículo del DiabetesCare ? https://t.co/Ex1NWpx3Y2 Hay que leerlo con cuidado, y por es…
RT @BebaVegaN: https://t.co/35lW93AgTw Ojo c/ partir tto sin supervición médica, hay pctes q comparten datos d fármacos sin evaluar los ri…
RT @BebaVegaN: https://t.co/35lW93AgTw Ojo c/ partir tto sin supervición médica, hay pctes q comparten datos d fármacos sin evaluar los ri…
https://t.co/35lW93AgTw Ojo c/ partir tto sin supervición médica, hay pctes q comparten datos d fármacos sin evaluar los riesgos d éstos. Dejo dato de Ozempic y riesgo de cáncer de tiroides. Sólo puedes usarlo bajo indicación médica! #cancerdetiroides #MinuevoYo #Ozempic https://t.co/TkflGjeu6E https://t.co/iuGu4gBny8
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
RT @DiabetesCareADA: A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased r…
A nationwide population-based study suggests that the use of GLP-1 receptor agonists is associated with an increased risk of thyroid cancer. #Pharmacoepi @DrugsSafe Read Here➡️https://t.co/s0PAaHPbq5 https://t.co/JOOd98Yo8i
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer https://t.co/sgUNKawHj2
https://t.co/8nQ9d9Sq4c
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Diabetes Care | American Diabetes Association https://t.co/r9mEpjugC5
RT @akkiii0830: GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Diabetes Care | American Diabetes Association https://t.co/9K1ZrcW…
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer | Diabetes Care | American Diabetes Association https://t.co/9K1ZrcWzkz
【コホート内症例対照研究】2次治療の抗糖尿病薬で治療されている2型糖尿病患者において、1-3年のGLP-1RAの使用は甲状腺癌のリスク増加と関連した。 #ペ読 https://t.co/ksupZYiPma
E
GM
DM
DA
PM
YR
L
MM
DF
MH
FN
AS
G
AE
DA
TP
IA
AH
LH
B
тс
T
GF
AA
AM
UA
НГ
HT
KK
T
MB
N
RM
?
PS
S
A
I
وا
T
J
C
D
ŁP
O
HJ
MR
ZM
JN
D糖
WH
D
DG
SI
JB
KS
HM
HM
EA
T
PL
R
D
CR
DP
LM
MS
A
LL
VM
?
リ医
JP
B
CT
MI
BS
FP
A
JM
ED
MC
MM
R
AG
S
MO
FQ
CP
HR
PS
FC
JG
HC
GU
L
SM
J
T
DF
AG
D
JC
LU
EC
OÁ
FZ
Y
EI
DS
DN
SD
RM
SS
DE
DS
CP
AB
DM
E
DM
AA
DK
L
MG
DJ
دا
DA
AA
DT
AO
AP
KM
AA
JM
CB
Aب
T
JB
A
ÁJ
AK
AB
RZ
AM
JH
DJ
BM
MC
AF
HC
RH
VV
J
AA
VA
YZ
CP
L
JM
VB
JF
D
A
ZB
RG
JB
LB
AB
小
名
P